Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated With Interferon Beta or Glatiramer Acetate

International Journal of Molecular Sciences- Switzerland

doi 10.3390/ijms21010218

Full Text

Abstract

Available in

Date

Authors

Publisher

MDPI AG

Related search

T-Cell Interferon Gamma Receptor Binding in Interferon Beta-1b–Treated Patients With Multiple Sclerosis

Archives of Neurology
1999English

Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Serum S100B in Primary Progressive Multiple Sclerosis Patients Treated With Interferon-Beta-1a

Journal of Negative Results in BioMedicine
GeneticsPharmacologyMolecular BiologyBiochemistryMedicineToxicologyPharmaceutics
2004English

Assessing the Long-Term Effectiveness of Interferon-Beta and Glatiramer Acetate in Multiple Sclerosis: Final 10-Year Results From the UK Multiple Sclerosis Risk-Sharing Scheme

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2018English

Pnd34 - Payer and Societal Benefit of Peginterferon Beta-1a Versus Glatiramer Acetate in Patients With Relapsing-Remitting Multiple Sclerosis in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd33 - Payer and Societal Benefit of Peginterferon Beta-1a Versus Glatiramer Acetate in Patients With Relapsing-Remitting Multiple Sclerosis in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Neutralizing Antibodies in Interferon Beta Treated Patients With Multiple Sclerosis: Knowing What to Do Now

Journal of Neurology
Neurology
2011English

Fludarabine Add-On Therapy in Interferon-Beta-Treated Patients With Multiple Sclerosis Experiencing Breakthrough Disease

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2016English

Glatiramer Acetate in the Reduction of Relapse Frequency in Multiple Sclerosis

Clinical Medicine Insights: Therapeutics
MedicinePharmacologyPharmaceutical Science
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy